So when MapLight Therapeutics revealed earlier this week that one of its experimental medicines had succeeded in a schizophrenia study, company leadership hoped investors would find the data as exciting as they did. MapLight “has a case for an important drug,” wrote Paul Matteis, from the investment bank Stifel, in a note to clients. So it’s really the effect size of 0.37 versus the effect size of 0.54 for Cobenfy. KROEGER: The cognitive composite score is looking at a bunch of different elements — really at reasoning and memory abilities. What I can say is, if you look at effect sizes, a 0.5 effect size is a robust change in that metric.